

Bimmer E Claessen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3211157/publications.pdf>

Version: 2024-02-01

208
papers

6,971
citations

66315

42
h-index

69214

77
g-index

260
all docs

260
docs citations

260
times ranked

6606
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	1.0	92
2	DEtection of ProxImal Coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration). <i>European Radiology</i> , 2022, 32, 143-151.	2.3	10
3	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 380-389.	1.0	4
4	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 20-29.	1.0	8
5	Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 631-641.	0.7	1
6	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. <i>Nature Reviews Cardiology</i> , 2022, 19, 195-208.	6.1	34
7	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
8	Identification and treatment of the vulnerable coronary plaque. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 1.	0.5	10
9	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. <i>American Journal of Cardiology</i> , 2022, 168, 47-54.	0.7	4
10	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. <i>Journal of Clinical Medicine</i> , 2022, 11, 1361.	1.0	14
11	Current State and Future Perspectives of Artificial Intelligence for Automated Coronary Angiography Imaging Analysis in Patients with Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2022, 24, 365-376.	1.3	6
12	Residual Inflammatory Risk After Percutaneous Coronary Intervention. <i>JACC Asia</i> , 2022, , .	0.5	0
13	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
14	Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2021, 6, 102-112.	3.0	19
15	Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusionâ€”A subanalysis of the EXPLORE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1176-1183.	0.7	2
16	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	1.4	40
17	Safety and efficacy of the bioabsorbable polymer everolimusâ€eluting stent versus durable polymer drugâ€eluting stents in highâ€risk patients undergoing PCI : TWILIGHTâ€SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	0.7	6
18	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. <i>International Journal of Cardiology</i> , 2021, 322, 65-69.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	0.7	8
20	A sex paradox in clinical outcomes following complex percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2021, 329, 67-73.	0.8	11
21	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1387-1396.	0.7	42
22	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 419-428.	1.0	2
23	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 649-657.	1.5	7
24	White blood cell count and clinical outcomes after left main coronary artery revascularization. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 45-51.	0.3	0
25	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2432-2447.	1.2	17
26	Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E494-E500.	0.7	2
27	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	0.7	7
28	Cangrelor Use in Routine Practice: A Two-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2829.	1.0	1
29	Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1009-1015.	0.4	30
30	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E785-E795.	0.7	2
31	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021, 42, 339-351.	1.0	57
32	The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement. <i>Journal of Invasive Cardiology</i> , 2021, 33, E823-E832.	0.4	0
33	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.	0.7	5
34	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	1.0	121
35	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. <i>European Radiology</i> , 2020, 30, 600-608.	2.3	13
36	Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 558-564.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2020, 125, 685-693.	0.7	1
38	TCT CONNECT-162 Predictors of Adverse Events in Patients Undergoing Cardiac Surgery Within 1 Year of PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, B69-B70.	1.2	0
39	TCT CONNECT-305 Impact of Lesion Location on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents for Unprotected Left Main Coronary Artery Stenosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, B131-B132.	1.2	0
40	TCT CONNECT-307 Long-Term Outcomes After Coronary Intervention With Drug Eluting Stents for Unprotected Left Main Coronary Artery Stenosis According to Diabetes Mellitus Status. <i>Journal of the American College of Cardiology</i> , 2020, 76, B132-B133.	1.2	1
41	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2020, 137, 1-6.	0.7	0
42	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 435-450.	1.2	7
43	IMPACT OF INCOMPLETE REVASCLARIZATION OF THE LEFT ANTERIOR DESCENDING ARTERY VERSUS OTHER CORONARY ARTERIES AFTER PCI: INSIGHTS FROM THE RIVER-PCI TRIAL. <i>Journal of the American College of Cardiology</i> , 2020, 75, 192.	1.2	0
44	FFR in the Setting of ACS. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1904-1906.	1.1	2
45	TCT CONNECT-379 Adverse Outcomes in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, B163.	1.2	0
46	Stent Technology Reaches Maturity?. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2879-2881.	1.1	1
47	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018897.	1.6	23
48	Implications of Kidney Disease in the Cardiac Patient. <i>Interventional Cardiology Clinics</i> , 2020, 9, 265-278.	0.2	2
49	Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1417-1428.	1.1	77
50	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	1.4	21
51	Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 298-308.	0.7	11
52	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INTERNATIONAL Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 198-207.	0.7	13
53	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E688-E694.	0.7	1
54	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28

#	ARTICLE	IF	CITATIONS
55	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020, 109, 725-734.	1.5	5
56	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014611.	1.6	12
57	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	1.2	93
58	RESIDUAL INFLAMMATORY RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1357.	1.2	0
59	IMPACT OF GENDER AND RACE ON OUTCOMES AFTER COMPLEX PERCUTANEOUS CORONARY INTERVENTION WITH THE PLATINUM-CHROMIUM EVEROLIMUS-ELUTING STENT: A POOLED ANALYSIS OF THE PLATINUM DIVERSITY AND PROMUS ELEMENT PLUS POST-APPROVAL STUDIES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1358.	1.2	0
60	TCT-307 Vascular Closure Device Use After PCI for Left Main Disease: Analysis From the EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B305.	1.2	0
61	TCT-315 White Blood Cell Count and 4-Year Clinical Outcomes After Left Main Coronary Artery Revascularization: Insights From the EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B313.	1.2	0
62	TCT-662 Patients Who Do Not Receive Drug-Eluting Stent for In-Stent Restenosis: Characteristics and Outcomes. <i>Journal of the American College of Cardiology</i> , 2019, 74, B650.	1.2	0
63	TCT-686 The Impact of Coronary Artery Disease and Pre-Procedural PCI on the Short- and Long-Term Mortality After TAVR. <i>Journal of the American College of Cardiology</i> , 2019, 74, B673.	1.2	0
64	TCT-214 Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Chronic Total Coronary Occlusions: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2019, 74, B213.	1.2	0
65	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. <i>International Journal of Cardiology</i> , 2019, 297, 22-29.	0.8	10
66	Minding the Microcirculation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008312.	1.4	0
67	Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report. <i>Journal of Radiology Case Reports</i> , 2019, 13, 9-14.	0.2	0
68	Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 82-90.	0.7	10
69	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	18.1	179
70	Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1941-1948.	0.7	9
71	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	0.7	35
72	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 983-992.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2401-2409.	1.2	69
74	600.09 In-Hospital Outcomes of Patients with Bicuspid Aortic Valve Undergoing Transcatheter Aortic Valve Replacement: A Nationwide Analysis. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, S45.	1.1	1
75	Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLORE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 536-545.	0.7	3
76	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. <i>International Journal of Cardiology</i> , 2019, 287, 59-61.	0.8	8
77	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	1.4	17
78	Hope for the best, prepare for the worst: How to manage coronary perforations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E255-E256.	0.7	2
79	Cardiology fellows-in-training are exposed to relatively high levels of radiation in the cath lab compared with staff interventional cardiologists' insights from the RECAP trial. <i>Netherlands Heart Journal</i> , 2019, 27, 330-333.	0.3	4
80	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 42-51.	1.0	5
81	IMPACT OF PERCUTANEOUS CORONARY INTERVENTION COMPLEXITY IN REAL-WORLD PRACTICE. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1274.	1.2	0
82	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1788-1795.	0.7	7
83	Leave nothing behind: Promising results for coronary drug-coated balloons in clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 189-190.	0.7	1
84	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1494-1500.	0.7	19
85	The link between anemia and adverse outcomes in patients with acute coronary syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 151-159.	0.6	10
86	Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion (from the EXPLORE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1035-1043.	0.7	6
87	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. <i>Clinical Research in Cardiology</i> , 2019, 108, 643-650.	1.5	21
88	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 709-716.	0.7	9
89	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.	0.7	2
90	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007411.	1.4	55

#	ARTICLE	IF	CITATIONS
91	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.	0.7	16
92	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 207, 10-18.	1.2	7
93	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019, 275, 31-35.	0.8	12
94	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	0.7	22
95	Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 216-221.	0.7	4
96	Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. <i>Heart</i> , 2018, 104, 1432-1438.	1.2	55
97	Long-term outcomes of a Caucasian cohort presenting with acute coronary syndrome and/or out-of-hospital cardiac arrest caused by coronary spasm. <i>Netherlands Heart Journal</i> , 2018, 26, 26-33.	0.3	10
98	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	0.8	6
99	Revascularization Strategies in Cardiogenic Shock Patients With MVD. <i>Journal of the American College of Cardiology</i> , 2018, 71, 857-859.	1.2	5
100	Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Long-Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator (the eCTOPY-IN-ICD Study). <i>Journal of the American Heart Association</i> , 2018, 7,	1.6	13
101	Patient delay in women with STEMI: Time to raise awareness. <i>International Journal of Cardiology</i> , 2018, 262, 30-31.	0.8	1
102	Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 511-512.	1.1	0
103	Reply. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 506-507.	1.1	0
104	Recurrent myocardial infarction in a 47-year-old woman with a mechanical mitral valve prosthesis: Atherosclerosis, embolism, or spasm?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 267-270.	0.7	0
105	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 275-283.	1.1	88
106	TCT-539 Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials. <i>Journal of the American College of Cardiology</i> , 2018, 72, B217.	1.2	1
107	TCT-835 Validation of PARIS Risk Scores in Patients Treated With Everolimus-Eluting Stents for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, B333.	1.2	1
108	Go With the Flow When Instantaneous Wave-Free Ratio-Fractional Flow Reserve Discordance Occurs. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2435-2436.	1.1	1

#	ARTICLE	IF	CITATIONS
109	TCT-736 Prevalence and Impact of Bleeding Determinants on Risks for out-of-hospital bleeding and coronary thrombosis in patients undergoing percutaneous coronary intervention: Results from a large single-center PCI Registry. <i>Journal of the American College of Cardiology</i> , 2018, 72, B295.	1.2	0
110	The quest for the optimal treatment for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 300-301.	0.7	1
111	Paravalvular Leak. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2149-2151.	1.2	6
112	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. <i>European Heart Journal</i> , 2018, 39, 4101-4108.	1.0	89
113	How to manage chronic total occlusions in the setting of acute myocardial infarction complicated by cardiogenic shock?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 464-465.	0.7	0
114	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1997-2005.	1.8	19
115	Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 825-835.	0.6	16
116	CTCA for detection of significant coronary artery disease in routine TAVI work-up. <i>Netherlands Heart Journal</i> , 2018, 26, 591-599.	0.3	50
117	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	0.7	18
118	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. <i>Open Heart</i> , 2018, 5, e000810.	0.9	11
119	Letter by Kikkert et al Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)" <i>Circulation</i> , 2018, 138, 214-215.	1.6	0
120	The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial. <i>Journal of Electrocardiology</i> , 2018, 51, 906-912.	0.4	6
121	Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2018, 122, 1661-1669.	0.7	8
122	Acute myocardial infarction, chronic total occlusion, and cardiogenic shock: the ultimate triple threat. <i>EuroIntervention</i> , 2018, 14, e252-e254.	1.4	3
123	Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2347-2348.	1.2	5
124	Impact of Collateral Circulation on Survival in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With a Concomitant Chronic Total Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 906-914.	1.1	30
125	Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients. <i>Netherlands Heart Journal</i> , 2017, 25, 429-438.	0.3	12
126	Culprit Vessel "Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	44

#	ARTICLE	IF	CITATIONS
127	Efficacy of the RADPAD Protection Drape in Reducing Operatorsâ€™ Radiation Exposure in the Catheterization Laboratory. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	48
128	TCT-387 Collateral quality decay several days after primary PCI: a novel observation from the EXPLORE trial. <i>Journal of the American College of Cardiology</i> , 2017, 70, B159.	1.2	2
129	Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 19, 53.	1.6	41
130	Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1100-E1102.	0.6	1
131	Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1622-1632.	1.2	300
132	A SMILE and a Frown. <i>Journal of the American College of Cardiology</i> , 2016, 67, 273-274.	1.2	8
133	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 441-451.	1.0	9
134	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. <i>EuroIntervention</i> , 2016, 12, 423-430.	1.4	8
135	Physiology-guided myocardial revascularisation in complex multivessel coronary artery disease: beyond the 2014 ESC/EACTS guidelines on myocardial revascularisation. <i>Open Heart</i> , 2015, 2, e000308.	0.9	5
136	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	1.8	11
137	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: Results of the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 335-342.	0.7	22
138	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention â€” From the PROTECT II randomized trial. <i>International Journal of Cardiology</i> , 2015, 189, 272-278.	0.8	9
139	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. <i>International Journal of Cardiology</i> , 2015, 187, 90-96.	0.8	126
140	A Dutch perspective on the ESC/EACTS guidelines on myocardial revascularisation. <i>Netherlands Heart Journal</i> , 2015, 23, 290-291.	0.3	2
141	Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. <i>Netherlands Heart Journal</i> , 2015, 23, 477-482.	0.3	8
142	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. <i>Interventional Cardiology Review</i> , 2015, 10, 39.	0.7	2
143	Focus on maximal miniaturisation of transradial coronary access materials and techniques by the Slender Club Japan and Europe: an overview and classification. <i>EuroIntervention</i> , 2015, 10, 1178-1186.	1.4	40
144	Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. , 2015, , 2281-2296.		0

#	ARTICLE	IF	CITATIONS
145	Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). <i>American Journal of Cardiology</i> , 2014, 113, 222-228.	0.7	116
146	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 155-164.	1.0	49
147	Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1081-1092.	1.1	159
148	TCT-196 Meta-Analysis on the impact of percutaneous coronary intervention of Chronic Total Occlusions on Long-term Mortality. <i>Journal of the American College of Cardiology</i> , 2014, 64, B58.	1.2	0
149	Contemporary overview and clinical perspectives of chronic total occlusions. <i>Nature Reviews Cardiology</i> , 2014, 11, 458-469.	6.1	33
150	Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Does Coronary Pressure Never Lie?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 294.	0.4	7
151	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 113, 229-235.	0.7	25
152	Does the Association Between a High Body Mass Index and Hospital Mortality Weigh Heavily on the Association Between a Low Body Mass Index and Hospital Mortality?. <i>Critical Care Medicine</i> , 2014, 42, e79.	0.4	0
153	Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. <i>EuroIntervention</i> , 2014, 10, 90-96.	1.4	26
154	Chronic Total Occlusions. , 2014, , 1-18.		0
155	The impact of multivessel disease with and without a coexisting chronic total occlusion on short- and long-term mortality in ST-elevation myocardial infarction patients with and without cardiogenic shock. <i>European Journal of Heart Failure</i> , 2013, 15, 425-432.	2.9	90
156	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 200-208.	1.0	6
157	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. <i>Interventional Cardiology Clinics</i> , 2013, 2, 515-525.	0.2	0
158	Vasoactive and Antiarrhythmic Drugs During Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2013, 2, 665-670.	0.2	0
159	Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 76-82.	0.7	46
160	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ</i> , The, 2013, 347, f6530-f6530.	3.0	194
161	Adjunctive thrombus aspiration versus conventional percutaneous coronary intervention in ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 922-929.	0.7	16
162	Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (>=75 Years). <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 85-92.	0.7	24

#	ARTICLE	IF	CITATIONS
163	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013, 8, 1033-1039.	1.4	25
164	Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013, 9, 220-227.	1.4	39
165	B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 813-820.	1.4	41
166	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. <i>European Heart Journal</i> , 2012, 33, 768-775.	1.0	206
167	Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1752-1759.	1.2	51
168	TCT-446 Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions in Elderly Patients (≥75 years): Five-Year Outcomes from a 1,791 Patient Multi-National Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, B128.	1.2	0
169	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1097-1105.	1.1	101
170	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1231-1238.	1.1	32
171	Plaque Composition by Intravascular Ultrasound and Distal Embolization After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S111-S118.	2.3	50
172	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 165-179.	1.0	14
173	Predictive Value of Plasma Glucose Level on Admission for Short and Long Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 53-59.	0.7	53
174	Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. <i>Journal of Invasive Cardiology</i> , 2012, 24, 484-8.	0.4	25
175	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2309-2316.	1.2	49
176	Prognostic Impact of Staged Versus One-Time Multivessel Percutaneous Intervention in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 704-711.	1.2	236
177	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 952-961.	1.1	260
178	Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1011-1019.	1.1	107
179	Impact of Intravascular Ultrasound Imaging on Early and Late Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 974-981.	1.1	106
180	Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1209-1215.	1.1	115

#	ARTICLE	IF	CITATIONS
181	Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. <i>American Heart Journal</i> , 2011, 161, 391-396.	1.2	58
182	Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1750-1756.	1.2	127
183	Two-Year Safety and Effectiveness of Sirolimus-Eluting Stents (from a Prospective Registry). <i>American Journal of Cardiology</i> , 2011, 107, 528-534.	0.7	4
184	Angioscopic and Virtual Histology Intravascular Ultrasound Characteristics of Culprit Lesion Morphology Underlying Coronary Artery Thrombosis. <i>American Journal of Cardiology</i> , 2011, 107, 1285-1290.	0.7	27
185	Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2011, 108, 924-931.	0.7	41
186	Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	28
187	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 654-664.	1.1	329
188	Thrombus Aspiration in Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 643-644.	1.1	1
189	Long-term safety and sustained left ventricular recovery: long-term results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2011, 6, 860-865.	1.4	26
190	Healing of a coronary artery dissection detected by intravascular ultrasound and optical coherence tomography. <i>EuroIntervention</i> , 2011, 7, 288-289.	1.4	2
191	Stents farmacolÃ³gicos eluidores de everolimus na prÃ¡tica no mundo real. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2011, 19, 351-352.	0.1	0
192	Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. <i>Interventional Cardiology</i> , 2010, 2, 757-759.	0.0	0
193	Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems. <i>Current Pharmaceutical Design</i> , 2010, 16, 4012-4024.	0.9	10
194	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?. <i>Netherlands Heart Journal</i> , 2010, 18, 451-453.	0.3	24
195	Relation of Multivessel Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction to Outcome and/or Non-Infarct Artery Intervention of a Chronic Total Occlusion. <i>American Journal of Cardiology</i> , 2010, 105, 902-903.	0.7	1
196	Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2010, 105, 955-959.	0.7	105
197	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. <i>Trials</i> , 2010, 11, 89.	0.7	58
198	Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. <i>Heart</i> , 2010, 96, 843-847.	1.2	60

#	ARTICLE	IF	CITATIONS
199	Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. <i>Heart</i> , 2010, 96, 1968-1972.	1.2	52
200	The Doppler flow wire in acute myocardial infarction. <i>Heart</i> , 2010, 96, 631-635.	1.2	14
201	Right ventricular dysfunction is an independent predictor for mortality in ST-elevation myocardial infarction patients presenting with cardiogenic shock on admission. <i>European Journal of Heart Failure</i> , 2010, 12, 276-282.	2.9	57
202	Current status of the Xience V [®] everolimus-eluting coronary stent system. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1363-1374.	0.6	11
203	In-Stent Restenosis in the Drug-Eluting Stent Era. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1897-1907.	1.2	663
204	One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort. <i>International Journal of Cardiology</i> , 2010, 145, 608-609.	0.8	0
205	Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission.. <i>Acute Cardiac Care</i> , 2010, 12, 51-57.	0.2	24
206	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 339-347.	1.4	109
207	Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1128-1134.	1.1	208
208	Prognostic Value of Free Plasma Homocysteine Levels in Patients Hospitalized With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 102, 135-139.	0.7	22